In the study presented here, WT lysozyme and the disease-associated variant F57I were expressed in the Drosophila CNS, with and without co-expression of SAP, to refine understanding of the in vivo consequences of the amyloidogenic F57I mutation and assess the impact of SAP in our model system of lysozyme amyloidosis. This evidence concerns the gene LYZ and amyloidosis.